Studies on animals and humans have demonstrated the IL-23/IL-17 association as a potential therapeutic target for various autoimmune diseases, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), and RA [221,226,227]. Here, IL17A is linked to autoimmune disease.